Search clinical trials for: Eyhance IOL

Total 6023 results

Second Affiliated Hospital of Soochow University

Recruiting

A Clinical Study of Recombinant Human Vascular Endothelial Inhibitor in Combination With PRaG for Advanced Refractory Non-small Cell Lung Cancer

Advanced Solid Tumor | Refractory Tumor

China
Fred Hutchinson Cancer Center

Recruiting

Ustekinumab for the Prevention of Acute Graft-versus-Host Disease After Unrelated Donor Hematopoietic Cell Transplant

Hematopoietic and Lymphoid System Neoplasm | Hematologic and Lymphocytic Disorder

United States
Washington University School of Medicine

Terminated

Allogeneic or Haploidentical Stem Cell Transplant Followed By High-Dose Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Leukemia, Myeloid, Acute

United States
Sidney Kimmel Cancer Center at Thomas Jefferson...

Completed

Safety and Efficacy Study of Immunotherapy With Rituximab and Interleukin-2 in Patients With Non-Hodgkin's Lymphoma

High Risk Non-Hodgkin's Lymphoma

United States
M.D. Anderson Cancer Center

Terminated

Haploidentical Natural Killer (NK) Cells With Epratuzumab for Relapsed Acute Lymphoblastic Leukemia (ALL)

Leukemia | Pediatric Cancer

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Enasidenib in Combination With Cobimetinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia

United States
Jennifer Eva Selfridge

Recruiting

Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Colorectal Cancer | Hodgkin Lymphoma | Acute Lymphoblastic Leukemia | Chronic Lymphocytic Leukemia | Non Hodgkin Lymphoma | Chronic Myeloid Leukemia | Plasma Cell Myeloma | Hematologic Malignancy | Rectum Cancer | Myeloproliferative Syndrome

United States
Rutgers, The State University of New Jersey
National Cancer Institute (NCI)

Terminated

Aldesleukin and Pembrolizumab in Treating Patients With Stage III-IV Melanoma

Metastatic Melanoma | Stage IV Skin Melanoma | Stage IIIB Skin Melanoma | Stage IIIC Skin Melanoma | Stage IIIA Skin Melanoma | Stage III Mucosal Melanoma of the Head and Neck | Stage IVA Mucosal Melanoma of the Head and Neck | Stage IVB Mucosal Melanoma of the Head and Neck | Stage IVC Mucosal Melanoma...

United States
National Cancer Institute (NCI)

Completed

Monoclonal Antibody Therapy With Sargramostim and Interleukin-2 in Treating Children With Neuroblastoma

Recurrent Neuroblastoma | Disseminated Neuroblastoma | Regional Neuroblastoma

United States
Endocyte

Completed

Safety and Tolerability Study of FolateImmune in Combination With Cytokines in Patients With Refractory or Metastatic Cancer

Cancer

United States
M.D. Anderson Cancer Center

Withdrawn

IPI-Biotherapy for Patients Previously Treated With Cytotoxic Drugs With Metastatic Melanoma

Melanoma
Gruppo Italiano Malattie EMatologiche dell'Adulto

Completed

Observational Evaluation of Infective Risk in Myelodysplastic Syndrome Patients

Myelodysplastic Syndrome

Italy
Assistance Publique - Hôpitaux de Paris

Withdrawn

Evaluation of the Pulmonary Vascular Reactivity Test in Patients With Pulmonary Arterial Hypertension and a Cardiac Shunt (ReVAch)

Pulmonary Arterial Hypertension With Congenital Cardiac Shunt
Henan University of Traditional Chinese Medicine
Jiangsu Famous Medical Technology Co., Ltd.

Unknown

Effect of Yong Chong Cao Capsule on Outcomes in Patients With Mild to Severe COPD

Pulmonary Disease, Chronic Obstructive

China
Seqirus
Novartis Vaccines

Completed

Dose Ranging Study to Evaluate Immunogenicity and Safety of Adjuvanted or Non-adjuvanted Cell Culture-derived H5N1 Influenza Vaccine in Young Adults (18-40 Years Old)

Influenza

United States, Germany
H. Lee Moffitt Cancer Center and Research Institute
Turnstone Biologics, Corp.

Recruiting

TBio-4101 and Pembro wi/ or w/o Chemo in Recurrent/Metastatic HNSCC

Squamous Cell Carcinoma of Head and Neck | Metastatic Squamous Cell Carcinoma

United States
James Isaacs, MD

Suspended

Efficacy & Safety for LN144 With Pembrolizumab With High Risk Stage IIIb-dResectable Melanoma

Stage IIIB Melanoma | Stage IIIC Melanoma | Stage IIID Melanoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI); Prometheus Laboratories; Key Biologics, LLC; Adelson...

Active, not recruiting

Lymphodepletion Plus Adoptive Cell Transfer With or Without Dendritic Cell Immunization in Patients With Metastatic Melanoma

Melanoma

United States
Masonic Cancer Center, University of Minnesota

Terminated

T-Cell Depleted Double UCB for Refractory AML

Acute Myelogenous Leukemia | Refractory Acute Myelogenous Leukemia

United States
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)

Completed

Cyclophosphamide, Fludarabine, and Total-Body Irradiation Followed By Cellular Adoptive Immunotherapy, Autologous Stem Cell Transplantation, and Interleukin-2 in Treating Patients With Metastatic Melanoma

Melanoma (Skin)

United States
Bristol-Myers Squibb

Completed

Abatacept and Infliximab in Combination With Methotrexate in Subjects With Rheumatoid Arthritis

Rheumatoid Arthritis

Spain, United States, Argentina, Brazil, Canada, Mexico, Peru, Korea, Republic of, Sweden, Australia, Russian Federation, Poland, Puerto Rico, Czech Republic, Denmark, South Africa, Switzerland
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Terminated

Therapeutic Autologous Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Metastatic Melanoma

Stage IV Melanoma

United States
University Health Network, Toronto
Merck Sharp & Dohme LLC

Completed

The ACTIVATE (Adoptive Cell Therapy InVigorated to Augment Tumor Eradication) Trial (ACTIVATE)

Advanced Ovarian Cancer | Malignant Melanoma

Canada
Masonic Cancer Center, University of Minnesota

Completed

Penostatin, Rituximab and Ontak and Allogeneic Natural Killer (NK) Cells for Refractory Lymphoid Malignancies

Chronic Lymphocytic Leukemia | Non-Hodgkin Lymphoma

United States
Masonic Cancer Center, University of Minnesota

Terminated

Chemotherapy, Total-Body Irradiation, Donor Natural Killer Cell Infusion, Aldesleukin, and UCB Transplant in Treating Patients With Relapsed or Refractory AML

Leukemia

United States
Nationwide Children's Hospital

Withdrawn

Autologous Stem Cell Transplant for Refractory Crohn's Disease

Crohn's Disease
National Cancer Institute (NCI)

Completed

Lymphocyte Re-infusion During Immune Suppression to Treat Metastatic Melanoma

Melanoma | Neoplasm Metastasis

United States
Eurofarma Laboratorios S.A.

Not yet recruiting

Study of Fluticasone/Formoterol/Glycopyrronium for the Treatment Chronic Obstructive Pulmonary Disease (TRIPLAR) (TRIPLAR)

Chronic Obstructive Pulmonary Disease

Brazil
John Harris

Recruiting

Using a Contact Dermatitis Model With Biologic Medications to Study Skin Inflammation

Allergic Contact Dermatitis | Skin Inflammation

United States
GlaxoSmithKline

Completed

Evaluating the Control of COPD Symptoms in Patients Treated With Tiotropium Bromide 18mcg Once Daily Alone, ADOAIR 50/250mcg Twice Daily Alone or ADOAIR 50/250mcg Plus Tiotropium Bromide 18mcg

Pulmonary Disease, Chronic Obstructive

Japan
FLUIDDA nv

Completed

Compare the Effects of Seretide® Evohaler and a Generic Salmeterol/Fluticasone Hydrofluoroalkane (HFA) Pressurized Metered-dose Inhaler (pMDI) on Functional Respiratory Imaging Parameters in Asthmatic Patients

Asthma

Belgium
MEDA Pharma GmbH & Co. KG

Completed

Dymista Allergen Chamber - Onset of Action Study

Seasonal Allergic Rhinitis

Canada
University of Dundee
AstraZeneca; NHS Tayside

Completed

Microbiome Use to Stratify Use of Inhaled Corticosteroids: MUSIC Trial (MUSIC)

Chronic Obstructive Pulmonary Disease

United Kingdom
Respirent Pharmaceuticals Co Ltd.
Becro Ltd.

Completed

A Bioequivalence Study Between Fluticasone and Salmeterol vs. SERETIDE DISKUS® in Healthy Volunteers With Charcoal Blockade

Bioequivalence

Greece
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes for Advanced HER2-Negative Breast Cancer

Breast Neoplasms

China
Fate Therapeutics

Terminated

FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors

Breast Cancer | Head and Neck Cancer | Colorectal Cancer | Pancreatic Cancer | Ovarian Cancer | Non Small Cell Lung Cancer | GastroEsophageal Cancer

United States
Fujian Cancer Hospital

Withdrawn

Phase II Trial of FOLFOXIGIL Versus FOLFOXIRI as First-line Therapy in Patients With mCRC

Metastatic Colorectal Cancer

China
National Cancer Institute (NCI)

Completed

Cholecalciferol and Genistein Before Surgery in Treating Patients With Early Stage Prostate Cancer

Prostate Adenocarcinoma | Stage I Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate Cancer

United States
St. Jude Children's Research Hospital
National Cancer Institute (NCI); Assisi Foundation

Completed

Pilot Study of Expanded, Donor Natural Killer Cell Infusions for Refractory Non-B Lineage Hematologic Malignancies and Solid Tumors

Leukemia, Myeloid, Acute | Myelodysplastic Syndrome | T-cell Lymphoblastic Lymphoma | Leukemia, Lymphocytic, Acute, T-Cell | Juvenile Myelomonocytic Leukemia Lymphoblastic

United States
Università Vita-Salute San Raffaele
Ospedale San Raffaele

Completed

Safety and Feasibility Study of Enhanced Recovery in Pancreaticoduodenectomy

Pancreatic Neoplasms

Italy
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes as Neoadjuvant Therapy for HER2-Negative Breast Cancer

Breast Neoplasms

China
CINJRegulatory
National Cancer Institute (NCI); Rutgers Cancer Institute of New Jersey

Terminated

High-Dose Aldesleukin and Ipilimumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed By Surgery

Recurrent Melanoma | Stage IV Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma

United States
Hoffmann-La Roche

Completed

OPERA Study: A Study of Two Dosing Regimens of CellCept (Mycophenolate Mofetil) in Kidney Transplant Patients.

Kidney Transplantation

France
National Cancer Institute (NCI)

Terminated

Gene Therapy Using Anti-Her-2 Cells to Treat Metastatic Cancer

Metastatic Cancer

United States
Yale University
Eisai Inc.

Completed

A Pilot Study to Determine the Safety of the Combination of Ontak in Combination With CHOP in Peripheral T-Cell Lymphoma

Peripheral T-Cell Lymphoma

United States
National Cancer Institute (NCI)

Terminated

Phase II Study of Metastatic Melanoma With Lymphodepleting Conditioning and Anti-gp100:154-162 TCR Gene Engineered Lymphocytes

Melanoma | Skin Cancer

United States
M.D. Anderson Cancer Center

Completed

Cisplatin, Temozolomide, Abraxane, With Interleukin-2 and Interferon for Metastatic Melanoma (BCAA)

Melanoma

United States
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

Phase I Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes as Neoadjuvant Therapy for HER2-Negative Breast Cancer

Breast Neoplasms

China
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Terminated

Therapeutic Autologous Lymphocytes, Aldesleukin, and Denileukin Diftitox in Treating Patients With Stage III-IV Melanoma

Recurrent Melanoma | Stage IV Melanoma | Stage III Melanoma

United States
Eisai Inc.

Completed

A Study of ONTAK and CHOP in Newly Diagnosed, Peripheral T-Cell Lymphoma

Lymphoma, T-Cell, Peripheral

United States

Search clinical trials for: Eyhance IOL

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Norway

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations